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ARTICLE OPEN
A Plasmodium berghei sporozoite-based vaccination platform
against human malaria
António M. Mendes1, Marta Machado1, Nataniel Gonçalves-Rosa 1, Isaie J. Reuling 2, Lander Foquet3,4, Cláudia Marques1,
Ahmed M. Salman5,6, Annie S. P. Yang2, Kara A. Moser7, Ankit Dwivedi7, Cornelus C. Hermsen2, Belén Jiménez-Díaz8, Sara Viera8,
Jorge M. Santos 1,12, Inês Albuquerque1, Sangeeta N. Bhatia9, John Bial10, Iñigo Angulo-Barturen8, Joana C. Silva7,11,
Geert Leroux-Roels3, Chris J. Janse5, Shahid M. Khan5, Maria M. Mota1, Robert W. Sauerwein2 and Miguel Prudêncio 1
There is a pressing need for safe and highly effective Plasmodium falciparum (Pf) malaria vaccines. The circumsporozoite protein
(CS), expressed on sporozoites and during early hepatic stages, is a leading target vaccine candidate, but clinical efﬁcacy has been
modest so far. Conversely, whole-sporozoite (WSp) vaccines have consistently shown high levels of sterilizing immunity and
constitute a promising approach to effective immunization against malaria. Here, we describe a novel WSp malaria vaccine that
employs transgenic sporozoites of rodent P. berghei (Pb) parasites as cross-species immunizing agents and as platforms for
expression and delivery of PfCS (PbVac). We show that both wild-type Pb and PbVac sporozoites unabatedly infect and develop in
human hepatocytes while unable to establish an infection in human red blood cells. In a rabbit model, similarly susceptible to Pb
hepatic but not blood infection, we show that PbVac elicits cross-species cellular immune responses, as well as PfCS-speciﬁc
antibodies that efﬁciently inhibit Pf sporozoite liver invasion in human hepatocytes and in mice with humanized livers. Thus, PbVac
is safe and induces functional immune responses in preclinical studies, warranting clinical testing and development.
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INTRODUCTION
The long-standing goal of an effective vaccine against malaria
constitutes a crucial component of efforts to prevent a disease
that continues to kill nearly half a million people per year.1 During
a natural malaria infection, Plasmodium sporozoites are injected
into the skin and skin vasculature by an infected mosquito and
travel to the liver of their vertebrate host. An asymptomatic
parasite maturation and replication phase inside hepatocytes
ensues, leading to the generation of Plasmodium exoerythrocytic
forms (EEFs) and preceding the release of erythrocyte-infectious
merozoites, which can establish a blood infection and lead to
disease symptoms [reviewed in2].
So far, vaccines against the early pre-erythrocytic stages of
Plasmodium parasites have shown most success among current
vaccine candidates,3 including the most advanced subunit vaccine
against the human malaria parasite P. falciparum (Pf), RTS,S, that
targets the circumsporozoite (CS) protein,4 the predominant
antigen on the surface of sporozoites and a major vaccine
candidate. While the ability of CS-based vaccination to partially
limit clinical malaria infection in the ﬁeld is a major achievement,
the modest and rapidly waning efﬁcacy of RTS,S stresses the
urgency to develop vaccines with higher and more durable
protection.5 An alternative to subunit vaccines is the use of whole-
sporozoite (WSp) approaches, based on the generation of
immunity against Plasmodium pre-erythrocytic stages following
immunisation with infective sporozoites under conditions that
prevent the appearance of clinical symptoms, including radiation-
attenuated sporozoites (RAS),6–8 genetically attenuated parasites
(GAP),9–13 and immunisation with non-attenuated sporozoites in
combination with chemoprophylaxis (CPS).14–16 Although CS has
been proposed to play an important protective role in WSp
vaccines, complete protection following P. yoelii RAS immuniza-
tion has been shown to occur in transgenic mice that are T-cell
tolerant to CS and cannot produce antibodies.17 Therefore,
protection induced by WSp is likely mediated by a plethora of
hitherto unidentiﬁed liver stage antigens presented to the
immune system during liver stage parasite development
(reviewed in18). Accordingly, later liver stage-arresting parasites,
such as some GAP parasites, and those completing liver stage
development, such as the CPS approach, seem to trigger
antimalarial immunity superior to that elicited by early-arresting
variants.11,19 Nonetheless, the most advanced WSp approach to
human vaccination relies on the intravenous administration of the
PfSPZ Vaccine, composed of aseptic, puriﬁed, cryopreserved
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PfRAS.20–23 While all current WSp human vaccination strategies
rely on the use of Pf sporozoites, alternative WSp vaccines can also
be envisaged. In this context, a rodent Plasmodium-based
immunization platform constitutes an inherently safe and hitherto
unexplored approach to WSp vaccination that is worth
investigating.
The paradigm of immunizing with non-pathogenic microorgan-
isms to protect against the disease caused by their human-
infective counterparts was pioneered by Edward Jenner using a
bovine poxvirus to prevent smallpox. This concept of vaccination
has since been employed for various other human diseases,
through the development of the bovine bacillus Calmette–Guérin
(BCG) vaccine against human TB or the selection of rhesus and
bovine rotavirus strains to create human rotavirus vaccines
(reviewed in24). Vaccine development has also beneﬁtted from
advances in genetic manipulation, which have allowed for
isolation, modiﬁcation, and optimization of vaccine antigen
delivery and facilitated smart vaccine design. The ﬁrst genetically
modiﬁed (GM) human vaccine, against hepatitis B, was approved
in 1986,25 followed by vaccines targeting inﬂuenza26 and Japanese
encephalitis.27 However, the combination of cross-species immu-
nity and genetic modiﬁcation has never been applied to the ﬁeld
of malaria vaccination.
We propose to use GM rodent Plasmodium sporozoites
expressing human Plasmodium antigens as a safe “naturally
attenuated” WSp vaccination platform that can elicit cross-
species immune responses against Pf as well as deliver speciﬁc
immunogens, such as PfCS, and that may protect against a
subsequent infection by human malaria parasites. Rodent P.
berghei (Pb) parasites efﬁciently infect human hepatocytes in vivo,
a requirement for optimal antigen presentation, while remaining
unable to cause a blood-stage infection, in agreement with the
widely accepted notion that they are non-pathogenic to humans.
We establish the proof-of-principle of this vaccination approach by
demonstrating that immunisation of rabbits with transgenic Pb
sporozoites expressing PfCS (PbVac) induces robust immunity
against Pf, including cross-species cellular immune responses, as
well as PfCS-dependent humoral responses that functionally block
Pf infection of liver-humanized mice. These results identify a new
Pb-based WSp immunizing agent and antigen delivery platform
for malaria vaccination and pave the way for the design of rodent
parasites that can induce optimal protective immune responses
against human malaria.
RESULTS
P. berghei can infect human hepatocytes but is unable to develop
in human erythrocytes
It is well known that the sporozoite stage of Pb is able to infect
hepatic cells from different hosts, including several human-
derived and mouse-derived hepatoma cell lines and human
primary hepatocytes (PH) cultured ex vivo [reviewed in28]. We
conﬁrmed and extended these ﬁndings by monitoring in parallel
the in vitro infection of one mouse and two human hepatoma cell
lines (Hepa 1-6, HepG2, and Huh7, respectively), and one human
immortalized hepatocyte line (HC-04), as well as the ex vivo
infection of human PH/ﬁbroblast co-cultures by Pb. Infection
assessed by immunoﬂuorescence microscopy showed that
sporozoites invade and develop to similar extents in all in vitro
systems studied (Fig. S1A-C) and that these parasites are able to
invade and develop inside human PH ex vivo (Fig. S1D-F). We
further ascertained Pb infectivity of human hepatocytes in vivo, in
liver-humanized FRG mice. Our results show that Pb can effectively
infect human hepatocytes engrafted in liver-humanized FRG mice
(Fig. 1a and Fig. S1G, H), displaying similar tropism to mouse and
human hepatocytes (Fig. 1b), and similar development inside
either type of cell (Fig. 1c and Fig. S1H).
We subsequently assessed Pb infectivity of human red blood
cells (RBC) employing blood-humanized mice, engrafted with
deﬁned proportions of human RBC,29 infected by transfusion of
infected RBC. Coupled use of nuclear SYTO-16 and mouse
erythroid line-speciﬁc TER-119 dyes allowed the distinction
between infected and non-infected cells and between human
and rodent RBC, respectively, and thereby enabling monitoring of
infection by ﬂow cytometry (Fig. 1d). Our results show that while
the SYTO-16+/TER-119+ population, indicative of infection of the
mouse RBC population, increased steadily, the SYTO-16+/TER-
119− population, corresponding to infected human RBC, remained
below 0.1%, similar to the background signal observed for mouse
RBCs in Pf-infected blood-humanized mice (Fig. 1d and e).
Fluorescence microscopy analysis of these samples revealed very
few SYTO-16+/TER-119− cells indicating the rare occurrence of
invasion of human RBCs by Pb (data not shown). We could not ﬁnd
any human RBC bearing a parasite with more than a single
nucleus, suggesting that the parasite degenerates into unviable
cryptic forms. To ascertain this, infected human and mouse RBC
were isolated by TER-119-based magnetic activated cell sorting
and the isolated cells were cultured in vitro for up to 20 h. Our
in vitro results show that while parasites in infected mouse RBC
were able to develop as expected, parasites in the infected human
RBC population remained single-nucleated and unable to multiply
(Fig. 1f). Similar results were obtained when infection of blood-
humanized mice was initiated by sporozoite injection (data not
shown). Overall, these results clearly show that Pb is capable of
infecting human hepatocytes whereas it is unable to develop
inside human RBC.
The PbVac vaccination platform
In order to assess the potential of Pb to elicit cross-species
immune responses against Pf, a comprehensive, in silico predic-
tion of CD8+ T cell epitopes in the proteomes of Pf and Pb was
carried out. Our results show that 24171 in silico-predicted
epitopes are shared between species. These are encoded in 61%
(3371/5548) of the Pf proteins and 66% (3332/5059) Pb proteins, of
which 3223 are orthologous pairs in the two species. This includes
several antigens expressed during pre-erythrocytic stages (e.g.,
SLARP, SIAP1, LISP1, and MB2), and substantiates the potential for
cross-protection between the two species (Fig. S2, Tables S1, S2).
Notably absent from the set of Pf proteins containing shared
epitopes with Pb is CS.
Given the established value of PfCS as a leading vaccine
candidate antigen, we generated a transgenic Pb line, PbVac, that
expresses PfCS, using ‘gene insertion/marker out’ (GIMO) methods
of transfection.30 The gene encoding PfCS was inserted into the
neutral 230p locus of the Pb genome under the control of the 5′-
and 3′ regulatory sequences of Pb’s upregulated in infective
sporozoites 4 (uis4) gene (Fig. S3A), which is expressed exclusively
in sporozoites and developing liver stages.31 The GIMO transfec-
tion method employed ensures the stable insertion of the gene
encoding the heterologous PfCS and ﬂanking regions in the Pb
genome, resulting in a drug-selectable marker-free transgenic
parasite.30 Genotyping of PbVac showed correct integration of the
PfCS expression cassette (Fig. S3B and C).
We next sought to assess the impact of genetic manipulation
on the overall ﬁtness of PbVac. To this end, we started by
evaluating PbVac’s sporogonic development and showed that it
was indistinguishable from that of the parental wild-type Pb
(PbWT), contrary to what was observed in previous attempts at
expressing PfCS as a replacement of the endogenous PbCS gene.32
The two parasite lines formed similar numbers of oocysts in the
mosquito host’s midgut (Fig. S4A), as well as of sporozoites in
oocysts (Fig. S4B), in the hemolymph (Fig. S4C), and in salivary
glands (Fig. S4D). We then analyzed the expression of the
endogenous PbCS and heterologous PfCS proteins, in PbVac and
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PbWT parasites. Immunoﬂuorescence microscopy analysis clearly
shows that only PbCS is expressed and shed by PbWT sporozoites
(data not shown), while the PbVac sporozoites express and shed
both the PbCS and the PfCS proteins during gliding (Fig. 2a). Our
results further show that both proteins are expressed by
developing PbVac parasites during hepatic development and are
present at the parasite membrane both in in vivo (Fig. 2b) and
ex vivo (Fig. S4E and F). We then compared the hepatic infectivity
of PbVac and PbWT sporozoites in mice. Immunoﬂuorescence
microscopy analysis of ex vivo-infected mouse PH revealed that
both parasites yield equivalent numbers of EEFs (Fig. S4G), which
have comparable development (Fig. S4H). Subsequent qRT-PCR
and immunoﬂuorescence microscopy analyses of infected mouse
livers further conﬁrmed that PbVac and PbWT sporozoites lead to
similar total hepatic parasite loads (Fig. S4I), with identical
numbers of EEFs formed (Fig. S4J) and similar in vivo development
(Fig. S4K). Additionally, we showed that, like PbWT, the PbVac
parasites readily infect human hepatocytes in liver-humanized
FRG mice (Fig. S5A and B) but, unlike Pf parasites, are unable to
multiply in human RBC, degenerating into unviable cryptic forms
Fig. 1 Rodent P. berghei parasites successfully develop within human hepatocytes but not within human RBCs. a Representative images of
developing rodent PbWT parasites in mouse (black square) and human (red square) hepatic cells of liver-humanized FRG mice 48 h post
infection (hpi) by iv injection of freshly isolated sporozoites. b Relative proportion of Pb-infected mouse (grey) and human (red) hepatocytes in
humanized FRG mice, normalized to the total humanization of the chimeric liver. c PbWT development in mouse (grey) and human (red)
hepatocytes 42 and 48 hpi of liver-humanized FRG mice. d Representative ﬂow cytometry plots of peripheral blood from blood-humanized
NSG mice infected by iv injection of Pf-infected (left) or Pb-infected RBCs (middle-left) before and after magnetic separation (middle-right and
right); Syto-16 for nucleic acids; TER-119 for murine erythroid lineage; imRBCs/ihRBCs: infected mouse or human RBCs; bimRBCs: background
signal for infected murine erythroid lineage. e Relative proportion of mouse and human RBCs infected with Pf (left) or Pb (right) parasites; bars
indicate standard error. f Representative pictures of Pb parasite forms observed within magnetically separated imRBCs and ihRBCs from the
total blood of infected blood-humanized NSG mice after 2 and 20 h of in vitro culture
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(Fig. S5C and D). Finally, we compared the infectivity of PbVac and
Pf sporozoites to freshly isolated human PH ex vivo. Our data
showed that the number of resulting EEFs in human PH, as
determined by microscopy 48 h after sporozoite addition, can be
up to 50-fold higher for PbVac than for Pf (Fig. 2c). Collectively, we
show that PbVac parasites display similar ﬁtness to PbWT and that
the engineered PfCS protein is correctly expressed, localizing to
the surface of PbVac sporozoites. Our results further show that
PbVac parasites are unable to develop inside human erythrocytes
and, most importantly, are able to infect human hepatocytes with
even greater efﬁciency than Pf.
An innovative animal model for evaluation of PbVac
immunogenicity
Having constructed and characterized the PbVac vaccine candi-
date, we then sought to assess its ability to elicit immune
responses against human-infective Pf parasites. Rodents do not
constitute an appropriate animal model in that respect, as they are
susceptible to blood-stage infection by PbVac. To overcome this
limitation, we evaluated New Zealand White (NZW) rabbits as an
alternative model that mimics Pb’s pattern of infectivity in
humans. To this end, we started by infecting NZW rabbit PH with
Pb sporozoites and assessed infection at different time points after
sporozoite addition by immunoﬂuorescence microscopy. The
results show that Pb effectively invades and develops inside
rabbit PH (Fig. 3a and Fig. S6A) and is capable of completing its
hepatic developmental process and forming infectious merozoites
ex vivo (Fig. 3b and Fig. S6B). To ascertain Pb’s ability to infect
rabbit hepatocytes in vivo, NZW rabbits were exposed to infected
mosquito bites or increasing numbers of Pb sporozoites injected
intravenously. qRT-PCR and detailed immunoﬂuorescence micro-
scopy analyses of rabbit livers showed that Pb readily infects
rabbit hepatocytes in an in vivo context (Fig. 3c) developing for a
longer period than the 58–62 h of development observed in
highly susceptible hosts such as BALB/c or C57BL/6 mice. Our
results further indicate that larger EEFs disappear from the rabbit
livers earlier than less developed parasites, which can be observed
up to 96 h after infection (Fig. 3d and Fig. S6C and D), therefore
appearing to persist longer than irradiated parasites do in the liver
of susceptible hosts (data not shown). Finally, to investigate rabbit
RBC infectivity by Pb, NZW rabbits were infected with luciferase-
expressing Pb sporozoites and blood samples were collected daily
and analyzed by Giemsa staining and luminescence. As controls,
mice were infected with similar numbers of Pb sporozoites and
blood samples were collected at the same time points. Our results
show that whereas parasitemia increased steadily in the blood of
infected mice, no parasites were detected in the NZW rabbit blood
up to 7 days after parasite administration (Fig. 3e). To fully
establish the inability of Pb to infect NZW rabbit RBC, rabbits and
mice were also infected by blood transfusion with 1 × 108 Pb-
infected mouse erythrocytes. Again, while parasitemia developed
as expected in the blood of infected mice, no parasites were
detected in rabbit blood (Fig. S6E) even following prolonged
treatment with phenylhydrazine to increase reticulocytemia (Fig.
S6F).
Immune responses elicited by immunization with PbVac parasites
Having shown that they constitute a model of Pb hepatic infection
that can be employed in immunization studies with Pb-based
sporozoite vaccines, NZW rabbits were immunized by repeated
mosquito bite delivery of PbWT or PbVac sporozoites for immune
response assessment. In parallel, non-infected mosquitoes were
allowed to feed on mock-immunized controls. Blood samples were
collected at the time of the 2nd and 3rd immunizations, as well as
one month after the 3rd and last immunization. Two to four
months after the last of three immunizations, rabbit blood and
splenocytes samples were collected for processing and subse-
quent analysis (Fig. 4a). We started by quantifying total IgGs in the
serum of immunized animals by ELISA, employing peptides
spanning the PfCS repeat region. Anti-PfCS antibody titers in the
serum of PbVac-immunized animals steadily increased after each
of the three immunizations, conﬁrming “vaccine take” in these
animals and successful delivery of the heterologous PfCS antigen
by PbVac (Fig. 4b). Anti-PbCS antibody titers measured as controls
Fig. 2 PfCS expression and human hepatic infectivity of PbVac pre-erythrocytic stages. a, b Representative Immunoﬂuorescence microscopy
images of PbCS (grey) and PfCS (purple) expressed by PbVac sporozoites a and exoerythrocytic forms in the livers of mice infected by iv
injection of freshly isolated sporozoites b. c Comparative infection rates of PbVac and Pf parasites in ex vivo cultures of human hepatocytes
assessed by immunoﬂuorescence microscopy. The shading of dots indicates distinct biological replicates obtained employing human
hepatocytes from different donors. The boxes correspond to the 25th and 75th percentiles; the lines and bars indicate mean of infection and
standard error of the mean, respectively; ***p < 0.001, as determined by Mann–Whitney U test. Scale bars: 10 µm
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in these experiments were also found to increase after each
immunization with either PbWT or PbVac, whereas neither anti-Pf
CS nor anti-PbCS antibodies were detected in mock-immunized
animals (Fig. S7A). Having shown that PfCS transgene presentation
upon immunization with PbVac leads to a strong humoral
response, we then investigated the responses elicited against
whole Pf sporozoites. Indirect ﬂuorescence antibody test (IFAT)
analyses of immune sera collected at various time points revealed
the presence of increasing amounts of antibodies that recognize
and bind to immobilized Pf sporozoites in the serum of PbVac-
immunized (Fig. 4c), but not in that of mock-immunized or PbWT-
immunized (Fig. S7B), rabbits. We then asked whether a CS-
speciﬁc cellular immune response was also induced by immuniza-
tion. To this end, rabbit splenic lymphocyte proliferation was
assessed by a 3H-thymidine incorporation assay following
stimulation with peptide pools spanning the entire amino acid
sequence of either the PbCS or the PfCS proteins. A marked
proliferation of lymphocytes of PbWT-immunized rabbits was only
observed in response to a PbCS stimulus, whereas those of PbVac-
immunized animals signiﬁcantly proliferated upon stimulation
with either PbCS or PfCS (Fig. 4d and Fig. S8). Of note, proliferation
was not observed when the cells were stimulated with peptides
spanning only the conserved repeat regions of the PbCS or PfCS
proteins (Fig. S8). Concomitantly, proliferation of lymphocytes
from immunized animals was assessed upon stimulation with
uninfected salivary gland material, PbWT, PbVac and Pf sporo-
zoites. Our data showed that lymphocytes from either PbWT-
immunized or PbVac-immunized rabbits signiﬁcantly responded
to both PbWT and PbVac sporozoite stimuli, whereas stimulation
with non-infected salivary gland material induced only basal levels
of thymidine incorporation (Fig. 4e and Fig. S8). As expected,
stimulations with sporozoites consistently induced more marked
lymphocyte proliferation than peptide-based stimulation. Lym-
phocytes from either group of immunized animals also incorpo-
rated signiﬁcantly more 3H-thymidine than those of mock-
immunized animals in response to a stimulus with Pf sporozoites,
indicating not only that immunization with PbVac elicits a strong
cellular response against Pf but also that this response occurs
likewise upon immunization with PbWT (Fig. 4e). These results are
in complete agreement with our ﬂow cytometry investigation of
cell proliferation in the presence of the different sporozoite stimuli
(Fig. S9 A-C). Furthermore, our results show that the cellular
immune responses observed in PbWT-immunized and PbVac-
immunized animals upon sporozoite stimulation contained a
Fig. 3 Infection of NZW rabbit hepatocytes with P. berghei sporozoites. a Rodent Pb parasite development 24 and 48 hpi in ex vivo cultures of
rabbit primary hepatocytes. b Representative immunoﬂuorescence microscopy image of a Pb merosomes developing ex vivo within rabbit
primary hepatocytes 60 hpi and presenting typical markers of late exoerythrocytic development. c qRT-PCR quantiﬁcation of hepatic infection
of rabbits following iv injection of increasing amounts of freshly isolated Pb sporozoites (1 × 105, 5 × 105, and 1 × 106). d Representative
immunoﬂuorescence microscopy images of rodent Pb parasites developing in the livers of NZW rabbits at different hpi. e Parasitemia in the
peripheral blood of rabbits (orange) or mice (grey) following iv injection of freshly isolated Pb sporozoites. Scale bars: 10 µm
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major CD4+ T cell component (Fig. S9C). Finally, augmented
lymphocyte proliferation capacity is concomitant with increased
IFNɣ production, as our results show that the amount of IFNɣ
produced upon stimulation of cells from sporozoite-immunized
animals, but not from mock-immunized animals, with any of the
sporozoite stimuli employed, was signiﬁcantly enhanced com-
pared to that of cells stimulated with non-infected salivary gland
material (Fig. 4f). Overall, these data indicate not only the
existence of cross-species cellular responses between Pb and Pf
but also that the PfCS protein engineered on the Pb background
contributes to the cellular, and mediates the humoral, immune
responses observed upon immunization with the PbVac parasite.
Functional capacity of PbVac-induced humoral immune responses
We next evaluated the ability of the observed immune responses
to inhibit infection by Pf. Since the protective capacity of the
cellular immune responses cannot be directly assessed because
the rabbit model employed is not susceptible to Pf infection, we
focused our analysis on the functionality of the humoral immune
responses elicited upon immunization. To this end, we performed
both in vitro inhibition assays and in vivo Pf challenge assays of
liver-humanized FRG mice employing IgGs isolated from the
serum of mock-, PbWT-immunized and PbVac-immunized rabbits
(Fig. 5a). Incubation of sporozoites with ~0.2 mg/ml post PbVac-
immunization IgGs led to a ~40% decrease in Pf infection of HC04
Fig. 4 Immune responses in NZW rabbits after PbVac sporozoite immunization. a Diagram of the immunization protocol. Immunizations were
performed by exposure to the bites of 75-100 mosquitoes. b Total IgG titers against PfCS repeat sequence in serum after 1, 2, and 3 mock
immunizations (grey), or immunization with PbWT (orange) and PbVac (purple), or at the time of animal sacriﬁce (S) 60–90 days after last
immunization. c Serum binding capacity to Pf sporozoites after PbVac immunization. d Spleen cell proliferation upon stimulation with peptide
pools spanning the entire PbCS or PfCS proteins in immunized rabbits, as indicated by assessment of 3H-thymidine incorporation. e Spleen cell
proliferation upon stimulation with PbWT, PbVac or Pf sporozoites, as indicated by assessment of 3H-thymidine incorporation. Stimulation with
an extract of uninfected mosquito salivary gland material was used as control. f IFNy production in rabbit spleen cell supernatant after
stimulation with PbWT, PbVac or Pf sporozoites. Measurements were taken from distinct samples. The boxes correspond to the 25th and 75th
percentiles; the line and bars indicate mean of infection and standard error of the mean, respectively; *p < 0.05; **p < 0.01; ***p < 0.001, as
determined by Kruskal–Wallis test, corrected with Dunn’s multiple comparisons test
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cells compared with IgGs from mock-immunized animals (Fig. 5b).
This effect is more pronounced than the impairment observed on
Pf sporozoite traversal following incubation with 10mg/ml total
IgGs from CPS-immunized volunteers.33 Finally, 10 mg total IgGs
puriﬁed from the serum of mock-, PbWT-immunized and PbVac-
immunized rabbits were injected into liver-humanized FRG mice.
Twenty-four hours after IgG passive transfer, these mice were
challenged by an equal number of Pf-infected mosquito bites. The
Pf load in the chimeric livers of humanized FRG mice was assessed
ﬁve days later by qRT-PCR. The results show that passive transfer
of 10mg IgGs from PbVac-immunized rabbits, but not from PbWT-
immunized or mock-immunized animals, conveyed near complete
protection against a subsequent Pf hepatic infection (Fig. 5c). This
decrease in liver parasite load is more marked than that observed
under similar experimental conditions following passive transfer of
10mg of IgGs from CPS-immunized volunteers, which is
equivalent to the typical IgG concentration in human plasma.33
Collectively, these data show that immunization with PbVac elicits
the production of high titers of functional antibodies, mostly
targeting the PfCS antigen, capable of preventing a subsequent
infection by human-infective parasites.
DISCUSSION
Despite being known for more than 100 years that attenuated
pathogens can induce protective immunity,24 the present study
introduces for the ﬁrst time a practical approach to developing a
human vaccine based on the concept of employing an avirulent
non-human Plasmodium parasite as a versatile platform of WSp-
based antigen delivery for vaccination against human malaria.
Although transgenic rodent malaria parasites where endogenous
antigens were replaced by those of their human-infective
counterparts have previously been described, they served
exclusively as tools for assessment of functional immunogenicity
of malaria vaccines rather than as antigen delivery plat-
forms.32,34,35 We now propose to use Pb as a safe, genetically
modiﬁable vaccination platform that can be engineered to express
multiple antigens of human malaria parasites capable of inducing
functional immune responses against different Plasmodium
species or various stages of the parasite’s life cycle.
We generated a new transgenic Pb parasite, PbVac, capable of
expressing and delivering the Pf immunodominant protective
antigen, PfCS.17,36 In a pre-clinical proof-of-principle study, we
show that immunisation with PbVac is effective against Pf through
a combination of cellular immune responses and antibody-based
responses. Consistent with the distribution of in silico-predicted
epitopes shared between the Pf and Pb proteomes, the induction
of T cell-mediated immunity by PbVac appears to be largely PfCS-
independent and arise from the vaccine’s Pb background. This is in
agreement with a recent study, in which peripheral blood T cell
responses to CS peptides were not detected following CPS
immunization of rhesus monkeys with P. knowlesi,37 as well as with
previous literature on cross-species immune responses in WSp
vaccination. In fact, the ﬁrst report of pre-erythrocytic cross-
species protection between Plasmodium species dates back to
1969, when mice immunized by injection of X-irradiated Pb
sporozoites were shown to be protected against a challenge with
viable sporozoites of P. vinckei.38 Protection was also observed
when Pb-immunized animals were challenged with rodent P.
chabaudi sporozoites and vice versa.39 In other studies, mice
immunized by irradiated or genetically attenuated (p36p−) Pb
sporozoites were shown to provide partial protection against
challenge by P. yoelii (Py) sporozoites,40 and 100% sterilizing cross-
species protection was observed when mice were immunized with
a late liver stage-arresting genetically attenuated Py parasite (Py-
abb/f) and challenged with Pb sporozoites.11 Sedegah et al.41
reported T cell-mediated protection of mice immunized with
attenuated Pb or Py sporozoites against heterologous challenge
with Py or Pb, respectively. The requirement for T cells to provide
protection against heterologous parasites was consistent with the
previous observation that a PyCS CD8+ T cell clone was protective
against challenge with the heterologous Pb sporozoites.42 Most
relevant in the context of the present study, immunization of mice
with Pf sporozoites protected the animals from infection with Pb.43
Protection was proposed to be mediated, at least in part, by
antibody cross-reaction between antigens other than PfCS and
PbCS, in agreement with the high genetic sequence similarity
between the two parasite species.44 However, it should be noted
that several examples of cross-species protective immune
responses induced by parasite components other than CS
following immunization with irradiated Plasmodium sporozoites
Fig. 5 PbVac-mediated protection against Pf challenge. a Diagram of
the experimental protocol. b Pf sporozoite infection of HC-04 human
immortalized hepatocyte cultures incubated with puriﬁed IgG from
mock- (grey), PbWT- (yellow) or PbVac (purple)-immunized rabbits. c
qRT-PCR quantiﬁcation of Pf hepatic infection inhibition in liver-
humanized FRG mice following passive transfer of puriﬁed IgGs from
mock (grey)-, PbWT (orange)- or PbVac (purple)-immunized rabbits
and challenge by the bites of 20 Pf-infected mosquitoes (n= 3 mice
per group). Measurements were taken from distinct samples. The
boxes correspond to the 25th and 75th percentiles in B), and the
minimum and maximum data range in C); the lines and bars indicate
mean of infection and standard error of the mean, respectively; *p <
0.05; **p < 0.01, as determined by one-way ANOVA, corrected with
Dunnett’s multiple comparisons test
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are available in the literature.45,46 Such protective antigens may
include, for instance, cell-traversal protein for ookinetes and
sporozoites (CelTOS),47 a protein that is highly conserved among
the Plasmodium species. Indeed, immunization of mice with
PfCelTOS has been shown to elicit cross-species protection against
a heterologous challenge with Pb.48 In humans, CS-speciﬁc cellular
immune responses were described in RAS-immunized volunteers
as determined by the proliferation of peripheral blood mono-
nuclear cells (PBMCs) upon in vitro stimulation with recombinant
Pf CS.49,50 Nevertheless, the reports of human immunization with
Pf sporozoites available so far do not show a correlation between
long-term protection afforded by WSp vaccines and CS-targeted
cellular immune responses, and correlations identiﬁed between
long-term protection and CS-targeted antibody responses20,21
have been interpreted as biomarkers of vaccine take rather than
mechanistic correlates. Thus, it is thought that long-term
protection induced by WSp is complex and likely mediated by
multiple liver stage antigens, whose identiﬁcation has been a
matter of previous research.47,51
Although protection by WSp immunisation may result from the
combined activities of induced T cells and antibodies against a
variety of antigens [reviewed in18], the presentation of a key Pf
antigen by the Pb vaccination platform may provide an additional
means of inducing targeted and effective immune responses.
Accordingly, our results show that immunization with PbVac elicits
a potent PfCS antibody response, capable of functionally inhibiting
infection of hepatocytes by Pf sporozoites. Humoral responses
induced by immunization with PbWT lack inhibitory activity
against Pf sporozoites, indicating a pivotal role of the PfCS protein
in the antibody-based protection conferred by vaccination with
PbVac. Unlike subunit approaches, a major advantage of the
expression of Pf antigens in Pb is that the latter is more likely to
generate full length Pf proteins that are correctly folded and post-
translationally modiﬁed, inducing a greater array of inhibitory
antibody responses against Pf sporozoites. Our ﬁndings are in
agreement with the fact that RAS immunization of human
volunteers leads to the production of high titers of antibodies
against the CS protein,49,52 which parallel the serum inhibitory
activity of sporozoite invasion of hepatoma cells in vitro.52
Moreover, antibodies against the immunodominant B-cell epitope
of PfCS were also shown to inhibit sporozoite infection in vitro53,54
and in vivo.55 Our results further indicate that the PfCS component
of the PbVac parasite may induce not only humoral responses but
also contribute to the overall cellular responses observed after
immunisation. In fact, CS-speciﬁc cellular immune responses have
been described in RAS-immunized volunteers as determined by
the proliferation of peripheral blood mononuclear cells upon
in vitro stimulation with recombinant PfCS.49,50 Additionally, an
epitope mapping to the 5′ repeat region of PfCS was identiﬁed in
T cell lines and clones obtained from a sporozoite-immunized
human volunteer,56 and another PfCS epitope was shown to be
recognized by human cytolytic class II-restricted CD4+ T cells.57
It is clear that WSp immunization offers several beneﬁts over
subunit vaccines, including the presentation of a wider range of
antigens, correctly folded and optimally delivered to their target
location. However, the success of Pf-based WSp vaccination
depends on the strict absence of breakthrough episodes, a
concern that is eliminated by Pb-based WSp antigen delivery
systems. Since Pb develops into maturing liver schizonts in human
hepatocytes, immunisation with Pb WSp vaccines is likely to result
in increased antigen exposure relative to early-arresting Pf-based
variants such as RAS or early-arresting GAP. We further observed
that PbVac sporozoites are 20–50 times more infectious than Pf,
likely increasing the effective dose of vaccination, and potentially
inducing robust immune responses with relatively few immuniz-
ing parasites. Moreover, Pb is highly amenable to genetic
manipulation, and several neutral loci have already been identiﬁed
in its genome. This raises the possibility of introducing multiple
antigens in the Pb platform, including those from different
human-infective Plasmodium spp., as well as blood-stage or
transmission-blocking antigens, placed under the control of a
strict pre-erythrocytic stage promoter.
The manufacturing of a PbVac vaccine suitable for future human
use can be envisaged to employ parenteral injection of
sporozoites obtained from mosquitoes that fed on PbVac-infected,
speciﬁc-pathogen free (SPF) rodents, previously infected with a
master cell bank of PbVac parasites that is fully certiﬁed as free of
human pathogens or other microbiological contaminants. A single
SPF rat can be used to infect more than one thousand mosquitoes,
potentially generating hundreds of vaccine doses. Importantly, the
production of a Pb-based vaccine can be achieved in the absence
of high-containment mosquito infection and handling facilities or,
possibly, in vitro, as suggested by previous proof-of-principle
studies.58,59
The data presented here employing the PbVac parasite provides
the proof-of-concept that immunisation with GM rodent malaria
parasites can potentially be used to protect against human
malaria. Given the limitations of available animal models to
predict the protective efﬁcacy of such a vaccination approach, this
can only be fully ascertained in clinical trials performed upon
addressing all relevant safety and regulatory issues.
MATERIALS AND METHODS
Animal experimental procedures
Male C57BL/6 and Balb/cByJ mice, aged six to eight weeks, as well as NZW
rabbits, aged four to six weeks, were purchased from Charles River and
housed in the animal facilities of Instituto de Medicina Molecular,
Faculdade de Medicina, Universidade de Lisboa, Portugal (iMM Lisboa).
Experimental procedures were performed according to the Federation of
European Laboratory Animal Science Associations (FELASA) guidelines and
iMM Lisboa regulations. Blood-humanized NSG mice were produced and
housed at the AAALAC-accredited GlaxoSmithKline Laboratory Animal
Science facility in Tres Cantos (Madrid, Spain). All the experiments were
approved by the GlaxoSmithKline Diseases of the Developing World Group
Ethical Committee and complied with Spanish and European Union
legislation on animal research and GlaxoSmithKline policy on the care and
use of animals. Liver humanized FRG mice were produced by Yecuris
(Tualatin, Oregon USA), and housed in the animal facilities of the Faculty of
Medicine and Health Sciences of the Ghent University or at iMM Lisboa.
The experimental protocol for Pf or Pb infection of these mice was
approved by the animal ethics committees of the Faculty of Medicine and
Health Sciences of the Ghent University and of iMM Lisboa (DGV-AWB-
2015-09-MP-Malaria). All facilities were kept under a 12 h light/dark period
at a temperature of 22 ± 2 °C and 40–70% relative humidity. Filtered tap
water and a γ-irradiated pelleted diet were provided ad libitum. In
experiments involving blood-stage infections, animals were euthanized at
the ﬁrst behavioral signs of onset of experimental cerebral malaria (ECM),
and this was considered the experimental endpoint, with all efforts made
to minimize animal suffering.
P. berghei and P. falciparum reference parasite lines
The following reference lines of the ANKA strain of Pb were used: line
cl15cy1, line 676m1cl1 (PbGFP-Luccon; see RMgm-29 in www.Pberghei.eu)
and line 1596cl1 (GIMOPbANKA mother line; see RMgm-687 in in www.
Pberghei.eu). PbGFP-Luccon expresses a fusion protein of GFP and
luciferase from the eef1a promoter60 and the GIMO-mutant contains the
hdhfr::yfcu positive–negative selection marker in the silent 230p locus.30
For Pf experiments, Pf NF54 asexual and sexual blood stages were cultured
in a semi-automated culture system. Sporozoites were obtained by
dissection of salivary glands from infected female Anopheles stephensi
mosquitoes, reared at iMM-Lisboa or at the Radboud University (Nijmegen,
Netherlands), and which had previously fed on gametocyte-carrying
infected mice for Pb infections or cultured gametocytes through standard
membrane feeding for Pf infections. Mosquito salivary glands were kept on
ice in D-MEM culture medium and homogenized with a grinder to release
the sporozoites, which were subsequently counted on a Neubauer
chamber.
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Generation and genotyping of transgenic P. berghei parasite,
PbVac
A transgenic Pb parasite line containing a Pfcs expression cassette in the
neutral 230p locus was generated using the ‘gene insertion/marker out’
(GIMO) technology as previously described.30,61 The Pfcs expression
cassette was introduced into the neutral 230p locus of the GIMO mother
line 1596cl1,30,61 using construct pL1988 (Fig. S3A). The pL1988 construct
contains the Pfcs coding sequence (CDS) under the control of the Pbuis4 5′
and 3′ UTR regulatory sequences ﬂanked by the 5′ and 3′ targeting
sequences for the 230p locus. This construct integrates by double
crossover homologous recombination and replaces the positive–negative
selectable marker (SM) (human dihydrofolate reductase:: yeast cytosine
deaminase and uridyl phosphoribosyl transferase (hdhfr::yfcu)) cassette in
the GIMO mother line 1596cl1 with the Pfcs expression cassette. The
expression cassette contains the Pfcs CDS, which was ampliﬁed by PCR
from Pf NF54 genomic DNA.62 The CDS is ﬂanked by the 5′ and 3′ promoter
and transcription terminator sequences of Pb UIS4, which were ampliﬁed
from Pb ANKA WT genomic DNA. The coding sequence of the Pfcs gene
was conﬁrmed by sequencing. The construct pL1988 was linearized by
digestion with by SacII before introduction into parasites of the GIMO
mother line 1596cl1 using standard methods of GIMO transfection.30
Transfected parasites were selected in mice by applying negative selection
by providing 5-ﬂuorocytosine (5-FC) in the drinking water of mice.
Negative selection results in selection of chimeric parasites where the
hdhfr::yfcu SM in the 230p locus is replaced by the Pfcs expression cassette
(Fig. S3A). Selected transgenic parasites (line 2266) were cloned by the
method of limiting dilution. Clone line 2266cl1 (PbANKA-PfCSPPbuis4) was
selected for further analysis. Correct integration of the construct into the
genome of transgenic parasites was analysed by diagnostic PCR analysis of
gDNA and Southern analysis of pulsed ﬁeld gel (PFG)-separated
chromosomes (Fig. S3B,C). Primer sequences are listed in Supplementary
Tables S3 and S4.
In vitro infection of human and mouse hepatoma cell lines
Human (Huh7, HepG2, and HC-04) and mouse (Hepa1-6) hepatoma or
immortalized hepatocyte cell lines were cultured in RPMI medium
supplemented with fetal bovine serum (FBS), 50 µg/mL Penicillin/
Streptomycin, 2 mM Glutamine 0.1 mM non-essential amino acids (Gibco)
at 37 °C with 5% CO2. Cells were infected 24 h after seeding, by adding 5 ×
104 freshly dissected sporozoites in supplemented RPMI medium contain-
ing Fungizone (1 µg/mL, Gibco), followed by a 5-min centrifugation at
3000 rpm. The number of infected hepatocytes was assessed by staining
for Plasmodium Hsp-70 (mAb 2E6) and indirect immuno-ﬂuorescence
analysis, as previously described.63
In vitro infection of mouse and rabbit PH
Mouse PH were isolated from livers of adult C57BL/6 male mice following
an adaptation of a previously described perfusion method.64 Brieﬂy, mouse
livers were initially perfused with 30–40mL of liver perfusion medium
(LPM, Gibco) at 37 °C and a controlled ﬂow rate of 7–9mL/min, through a
cannula inserted in the portal vein, followed by digestion with 30–40mL of
liver digest medium (LDM, Gibco). The liver was then transferred to a cell
culture dish containing 10mL of LDM, its capsule membrane removed and
shaken to release loose cells. The cell suspension was then serially passed
through 100 and 70 µm cell strainers, washed twice with 30mL 4% (v/v)
FBS supplemented William’s E Medium (Gibco) at 30 g for 3 min at 20 °C
and puriﬁed by layering over a 60% Percoll gradient (GE Healthcare),
followed by centrifugation for 20min at 750 g, 20 °C, with no break.
Puriﬁed viable hepatocytes were counted with Trypan blue and plated on
collagen-coated plates before infection with freshly dissected Pb
sporozoites (1 × 105 hepatocytes infected with 7 × 104 sporozoites). An
adaptation of the mouse PH isolation protocol described above was
applied for isolation of rabbit PH. Brieﬂy, animals were euthanized by
injection of 150mg/kg IV Sodium Pentobarbital (Eutasil, CEVA), exsangui-
nated by direct heart puncture and immediately opened to begin the
process of liver perfusion. The portal vein was cannulated with a 21G
needle and the inferior vena cava cute for outﬂow. Perfused occurred with
400–500mL of liver perfusion medium (LPM, Gibco) at 37 °C followed by
digestion with 400–500mL of liver digest medium (LDM, Gibco) at a ﬂow
rate of 18mL/min, controlled by a peristaltic pump. The liver was carefully
removed, cut in small pieces and gently shaken to release loose cells. The
cell suspension was then treated identically to mouse PH to isolate puriﬁed
viable hepatocytes which were plated on collagen-coated plates and
allowed to settle and attach overnight. Pb infection and development was
assessed by immunoﬂuorescence using mouse anti-Plasmodium Hsp-70
(mAb 2E6), rabbit anti-Pb MSP1, goat anti-Pb UIS4, mouse anti-Pb CS (mAb
3D11) and mouse anti-Pf CS (mAb 2A10) and appropriate secondary
antibodies, as previously described.63
In vitro infection of human PH
Pb and Pf infection of human PH was performed on either micropatterned
co-culture (MPCC) preparations as previously described65 or on cultures of
fresh primary human hepatocytes isolated from patients undergoing
partial hepatectomy. Brieﬂy, for micropatterned co-cultures, 1 × 104
cryopreserved primary human hepatocytes (Life Technologies) were
seeded on collagen-micropatterned plates softlithographically patterned
with 500 µm islands together with 7 × 103 3T3-J2 murine embryonic
ﬁbroblasts. One day after seeding, 7 × 104 freshly dissected Pb sporozoites
were added to each well and subsequently, cells were ﬁxed at various time
points post infection for immunoﬂuorescence microscopy analysis. For
fresh primary human hepatocyte culture, viable hepatocytes were seeded
into collagen-coated 96-well ﬂat-bottom plates (5 × 104 hepatocytes/well)
in complete William’s B medium and cultured at 37 °C in an atmosphere of
5% CO2. Two days after seeding, a batch of 5 × 10
4 freshly dissected Pf or
Pb sporozoites were added to each well. Cells were ﬁxed 2 and 5 days after
infection for Pb and for Pf, respectively. The number of infected
hepatocytes was assessed by staining for Plasmodium Hsp-70 (mAb 2E6)
and indirect immunoﬂuorescence analysis.
In vivo infection of liver humanized FRG mice
Highly repopulated FRG mice were obtained from Yecuris (Tualatin, Oregon,
USA), as previously described.66 Brieﬂy, six-to-eight weeks old mice received
an injection in the spleen of cryopreserved human hepatocytes from a
single donor. The mice were then subjected to standardized NTBC (2-(2-
nitro-4-triﬂuoromethylbenzoyl)-1,3-cyclohexanedione) withdrawal regimen.
Starting eight weeks post transplantation, human albumin levels are
monitored using the Bethyl Laboratory Quantitative Human Albumin ELISA
Kit (Catalog #E90-134) according to the manufacturer’s protocol. Mice with
albumin levels above 5mg/mL, corresponding to <95% repopulation, were
included in the study. For Pb infection, liver chimeric FRG humanized mice
were injected respectively with 2 × 106 sporozoites or uninfected mosquito
salivary glands as control. Mice were euthanized 48 h post infection and
parts of the liver were either preserved in RNAlater, or placed in 4%
paraformaldehyde for 24 h, after which they were stored in PBS and further
processed to parafﬁn blocks. For microscopy analyses of Pb-infected livers,
liver sections were either stained with hematoxylin and eosin following
standard procedures or a combination of anti-PbUIS4 antibody and anti-
fumarylacetoacetate hydrolase (Yecuris®) and/or by anti-hepatocyte speciﬁc
antigen antibody (OCH1E5, Santa Cruz®). For Pf challenge, mice received an
intraperitoneal injection of either 10mg rabbit IgG puriﬁed from
immunized rabbits, or PBS, in an adaptation of a previously established
methodology.33 Brieﬂy, IgG puriﬁcation from 3–8ml plasma samples was
performed using Ab SpinTrap columns (GE Healthcare Life Sciences),
according to the manufacturer’s instructions and puriﬁed IgGs were further
concentrated to 200 µl using Amicon Ultra-0.5 Centrifugal Filter Units with
Ultracel-30 membrane (Millipore) also according to the manufacturer’s
instructions. Twenty-four hours after injection, animals were exposed to the
bites of 20 Pf-infected mosquitoes for 20min. Successful blood feeding and
sporozoite presence was conﬁrmed by mosquito dissection after the
challenge experiment. Five days later, mice were euthanized and liver
parasite burden (ring stage equivalent parasites (Pf) per 106 human
hepatocytes) was determined as previously described.67 Each liver was
divided into 12 sections, of which 25mg tissue was weighed and DNA was
extracted into 100 µL elution buffer with the High Pure PCR Template
Preparation Kit (Roche, Zaventem Belgium). Pf DNA levels were quantiﬁed
using a highly sensitive qPCR assay. qPCR was also employed to assess the
degree of repopulation with human hepatocytes of the chimeric livers, and
to normalize the Pf copy numbers.
In vivo infection of blood-chimeric humanized mice
Highly engrafted mice with human erythrocytes (hE) were obtained and
infected as previously described.29 Brieﬂy, NOD-scid IL-2Rγnull mice (NSG)
obtained from Charles River laboratories were injected i.p. daily through-
out the experiment with hE. When 60–70% chimerism in peripheral blood
was reached (7–10 days after initiation of injections), the mice were
infected by iv injection of 1 × 107 parasites obtained from infected donors
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or 5 × 105 freshly dissected sporozoites (not shown). Parasitemia was
measured during the following days by ﬂow cytometry analysis of 2 µl of
blood collected from the tail lateral vein of infected mice as previously
described.68 Blood was rapidly transferred into 0.1 ml of saline containing
2.5 or 5 µM SYTO-16 (for Pb) and 10 µg/ml TER119-PE (for murine erythroid
lineage), and incubated for 20min at room temperature in the dark. Ten
microliter of saline containing 0.25% (w/v) glutaraldehyde was then added
to each sample and incubated for an additional 5 min for complete
Plasmodium inactivation. The samples were then analysed on FACScalibur
or LSRII ﬂow cytometers (Becton Dickinson). Erythrocytes were gated
based on side scatter and forward scatter analysis, followed by a key
compensation step for SYTO-16 to accurately deﬁne the region of infected
events by comparison of the effect of increasing compensation of the
emission of SYTO-16 in samples from uninfected and Plasmodium-infected
mice. Results were analyzed using either CellQuest-Pro or BD FACSDiva 5.0
(Becton Dickinson) software. Microscopic analysis of samples of peripheral
blood from infected mice was simultaneously performed in blood smears
stained with 10% (v/v) Giemsa in saline buffer (0.015M NaCl, 0.001 M
phosphate buffer, pH 7.0).
In silico identiﬁcation of CD8+ T cell epitopes in the Pf and Pb
proteomes
The complete proteomes of Pf and Pb, consisting of 5548 and 5076
annotated proteins, respectively, were downloaded from PlasmoDB
(v36).69 CD8+ T cell epitope prediction was performed with the package
NetMHCpan (v4.0),70 and was based on ten alleles representative of the
HLA-A and HLA-B supertypes, with allele frequencies as described in the
Allele Frequency Net Database,71 accessed on 22 February 2018. Peptide
lengths of 9, 10, and 11 residues were used to search for 9 residue-long
core epitopes. Reported results are based only on strong binders, which
are deﬁned as those in the top 0.5% of afﬁnity binding prediction scores,
according to best practices.
Data availability
The datasets generated during and/or analysed during the current study
are available from the corresponding author on reasonable request.
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